


Protalix BioTherapeutics, Inc. (PLX)

NYSE; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001006281

Protalix BioTherapeutics, Inc. PLX; healthcare	
Grade	D/E  on the D/E boundary of 371 graded peers percentile 77.8; sampling error 2.5 points; lower is stronger
Rank	289 of 371
Profitability	D  percentile 69.9
Solvency	D  percentile 63.3
Growth and financing	C  percentile 43.1
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$82.3M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: distress, fortress balance sheet
Inputs computable	8 of 14
Graded from	filings received through Mar 18, 2026 205 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	\$2.69 2026-10-08; market equity \$216.7M
Price used in grade	None



D/E, the sloth

on the D/E boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: E from Mar 21, 2023, E from Mar 21, 2024, D from Mar 21, 2025, D/E from Mar 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 18, 2026

We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. ProCellEx®, our unique, proprietary plant cell-based protein expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Our corporate strategy

includes development of treatments for rare and orphan diseases.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 69.9						
Gross profitability		31.3%	32.2%	48.2	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		6.9%	(6.6%)	89.6	811	2025-12-31
Gross margin stability, five years		5.3 pts	2.8 pts	71.9	243	2025-12-31
Solvency, sleeve percentile 63.3						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(11.01)	(0.31)	64.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31
Current ratio		2.51x	2.96x	62.6	839	2025-12-31
Growth and financing, sleeve percentile 43.1						
Revenue growth, three-year compound		3.5%	10.0%	63.0	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000 pretax income must exceed the validity floor and imply a 0%-100% tax rate
Reinvestment rate		not computable	37.1%			
Asset growth, three years		13.9%	2.1%	27.2	704	2025-12-31
Net share issuance, one year		3.3%	2.5%	39.0	634	2026-03-01

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
284	Tilray Brands, Inc. (TLRY)	76.5	D	fortress balance sheet
285	Baxter International Inc. (BAX)	76.8	D	
286	Vivos Therapeutics, Inc. (VVOS)	77.0	D	dilution, short runway, late filer
287	Quest Diagnostics Inc. (DGX)	77.3	D	
288	biote Corp. (BTMD)	77.6	D/E	
289	Protalix BioTherapeutics, Inc. (PLX) <	77.8	D/E	
290	Femasys Inc. (FEMY)	78.1	D/E	dilution, short runway
291	X4 Pharmaceuticals, Inc. (XFOR)	78.4	D/E	dilution, fortress balance sheet
292	Milestone Scientific Inc. (MLSS)	78.6	D/E	late filer
293	Gilead Sciences, Inc. (GILD)	78.9	D/E	
294	C4 Therapeutics, Inc. (CCCC)	79.2	D/E	dilution, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	15.8%	8.0%	55
Distance from 52-week high	(14.3%)	(31.4%)	74
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(6.3%)	(1.0%)	38
Book value to price	0.33	0.28	55
Sales to price	0.24	0.31	44
Composite equity issuance, five years	57.4%	20.3%	67
Relative strength against the sector, log excess return	(0.07)	(0.14)	55

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$27.4M
Operating cash flow, four quarters	\$9.9M
Months of runway	not finite
Days since last periodic filing	58 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	\$1.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	\$52.7M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
2	cost of revenue	us-gaap:CostOfRevenue	\$27.0M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
3	assets	us-gaap:Assets	\$82.3M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
4	net income	us-gaap:NetIncomeLoss	-\$6.6M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$12.0M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
6	assets	us-gaap:Assets	\$73.4M	2024-12-31	2026-03-18	10-K	0001104659-26-029858
7	revenue	us-gaap:Revenues	\$53.4M	2024-12-31	2026-03-18	10-K	0001104659-26-029858
8	cost of revenue	us-gaap:CostOfRevenue	\$24.3M	2024-12-31	2026-03-18	10-K	0001104659-26-029858
9	revenue	us-gaap:Revenues	\$65.5M	2023-12-31	2026-03-18	10-K	0001104659-26-029858
10	cost of revenue	us-gaap:CostOfRevenue	\$23.0M	2023-12-31	2026-03-18	10-K	0001104659-26-029858
11	revenue	us-gaap:Revenues	\$47.6M	2022-12-31	2025-03-17	10-K	0001558370-25-003039
12	cost of revenue	us-gaap:CostOfRevenue	\$19.6M	2022-12-31	2025-03-17	10-K	0001558370-25-003039
13	revenue	us-gaap:Revenues	\$38.4M	2021-12-31	2024-03-14	10-K	0001558370-24-003161
14	cost of revenue	us-gaap:CostOfRevenue	\$16.3M	2021-12-31	2024-03-14	10-K	0001558370-24-003161
15	current assets	us-gaap:AssetsCurrent	\$66.7M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
16	current liabilities	us-gaap:LiabilitiesCurrent	\$26.5M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$385.0M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
18	operating income	us-gaap:OperatingIncomeLoss	-\$5.5M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
19	book equity	us-gaap:StockholdersEquity	\$48.2M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
20	liabilities	us-gaap:Liabilities	\$34.1M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
21	operating income	us-gaap:OperatingIncomeLoss	-\$23.7M	2015-12-31	2018-03-06	10-K	0001144204-18-013053
22	interest expense	us-gaap:InterestExpense	\$3.5M	2015-12-31	2016-03-08	10-K	0001144204-16-086642
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.6M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.7M	2024-12-31	2026-03-18	10-K	0001104659-26-029858
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.3M	2024-12-31	2026-03-18	10-K	0001104659-26-029858
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$1.3M	2023-12-31	2026-03-18	10-K	0001104659-26-029858
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.1M	2023-12-31	2026-03-18	10-K	0001104659-26-029858
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$25.0M	2022-12-31	2025-03-17	10-K	0001558370-25-003039
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$628,000	2022-12-31	2025-03-17	10-K	0001558370-25-003039
30	depreciation amortization	us-gaap:Depreciation	\$1.5M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$5.5M	2025-12-31	2026-03-18	10-K	0001104659-26-029858
32	income tax	us-gaap:IncomeTaxExpenseBenefit	\$996,000	2025-12-31	2026-03-18	10-K	0001104659-26-029858
33	current assets	us-gaap:AssetsCurrent	\$60.1M	2024-12-31	2026-03-18	10-K	0001104659-26-029858
34	current liabilities	us-gaap:LiabilitiesCurrent	\$25.6M	2024-12-31	2026-03-18	10-K	0001104659-26-029858
35	assets	us-gaap:Assets	\$84.4M	2023-12-31	2025-03-17	10-K	0001558370-25-003039
36	assets	us-gaap:Assets	\$55.8M	2022-12-31	2024-03-14	10-K	0001558370-24-003161
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	80,571,642	2026-03-01	2026-03-18	10-K	0001104659-26-029858
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	78,032,585	2025-03-14	2025-03-17	10-K	0001558370-25-003039